Increasing evidence suggests that percutaneous coronary intervention with newer generation drug-eluting stents may be an acceptable alternative, or even preferred in selected cases to the surgical approach, in patients with left main disease. This review will discuss the anatomic factors, the clinical variables, and the procedural strategies to consider, including physiology assessment and imaging guidance, in order to optimize outcomes. There was similar mortality risk based on creatinine clearance, peripheral vascular disease, and in those with UPLM disease [12] .
| I N TR ODU C TI ON
European and U.S. guidelines currently recommend the coronary-artery bypass grafting (CABG) as the preferred strategy to treat patients with unprotected left main (UPLM) coronary artery disease (CAD) [1, 2] .
Thus, percutaneous coronary intervention (PCI) should be considered when the coronary disease is technically favorable (i.e., in the absence of complex and diffuse lesions) [1, 2] Both guidelines are substantially based on the 705 patient subgroup with UPLM in the SYNTAX trial [3] , and on the findings of a few randomized trials, such as the LE MANS (100 patients) [4] , the PRECOMBAT (600 patients) [5] , and the study from Boudriot and colleagues (201 patients) [6] . Two additional large randomized controlled trials [7, 8] and long term data of the previous studies [9] [10] [11] have been recently published, fueling the ongoing debate on the subject. Aim of the present manuscript is to describe the technique of UPLM PCI that should be implemented to optimize the outcome.
| Current role of PCI for left main disease
Current U.S. multidisciplinary guidelines give a general indication to CABG for all those conditions in which revascularization of complex CAD, especially when involving the proximal left anterior descending (LAD) artery, can improve survival [1] . European guidelines give a class IB indication to CABG for the treatment of UPLM, regardless of the extent of CAD; class IB to PCI only in the case of SYNTAX score <22, class IIa for SYNTAX score 23-32, and class IIIB for SYNTAX score >32 as well as for left main disease plus 2 or 3 vessel disease [2] .
Although use of the SYNTAX score is recommended to assist evaluation [1, 2] , it does not account for clinical variables. In this regard the SYNTAX score may include high-risk patients in anatomically low-risk groups, and vice versa [12] . To overcome these limitations, numerous risk scores have been developed which incorporate clinical variables.
Perhaps, the most developed of these (and most useful, since it is the only score to further discriminate between PCI vs. CABG outcomes) is the SYNTAX score II [12] . In a post hoc analysis, the SYNTAX investigators applied a multivariable Cox proportional hazards model to the SYNTAX trial patient population to identify baseline clinical features associated with 4-year mortality following CABG or PCI [12] . Mortality risks were relatively lower for CABG versus PCI in patients with higher SYNTAX scores, triple vessel disease, younger age, reduced left ventricular ejection fraction, and female gender. Conversely, mortality risks were relatively lower for PCI versus CABG in patients with lower SYN-TAX scores, older age, and chronic obstructive pulmonary disease.
There was similar mortality risk based on creatinine clearance, peripheral vascular disease, and in those with UPLM disease [12] .
A further important finding from the SYNTAX score II analysis was that the presence of diabetes mellitus did not independently discriminate between PCI versus CABG for 4-year mortality. Although patients with diabetes who underwent revascularization had a higher rate of death, this risk was present for both PCI and CABG, suggesting that the worse prognosis in patients with diabetes and the relative benefit with CABG versus PCI is effected through comorbidities and the presence of advanced CAD. The SYNTAX score II analysis suggests that PCI may be an acceptable revascularization modality for patients with diabetes with appropriately non-complex CAD and other favorable clinical characteristics (see Table 1 for details) [13] .
| T ECH N I CA L C ONSI D ER A TI ON S

| Selection of DES
In the SYNTAX trial, target vessel revascularization (TVR) drove the increased major adverse cardiac and cerebrovascular events rate of PCI as compared to CABG [5] . Furthermore, in the PCI arm of the SYNTAX trial, with the first-generation TAXUS paclitaxel-eluting stent (PES), at 5 years, the rate of definite or probable stent thrombosis was >10%, with 19.4% of stent thromboses occurring in the left main artery. These stent thrombosis-related events contributed to cardiac death, myocardial infarction (MI), or all-cause revascularization in 5.1% of PCI-treated patients.
Fluoropolymer coated everolimus-eluting stents (EES) have a substantially lower stent thrombosis rate than first-generation drug-eluting stents (DES). In a large pooled analysis from four randomized trials [14] , treatment with EES compared to PES was associated with a 70% reduction in the rate of definite or probable stent thrombosis at 2 year follow-up. An analysis of the SPIRIT III and IV trials [15] found that target lesion was reduced by EES compared with PES in patients with both single-vessel disease and multi-vessel disease. Although extending these considerations to other second or even third generation DES cannot be done automatically, overall these studies suggest that recent improvements in stent technology have enhanced both safety and efficacy.
Among these improvements, the introduction of devices dedicated to the treatment of bifurcations has actually unfulfilled the promises of being more effective than conventional DES, thus, at the moment, a specific indication for these devices is rather unclear [16] .
On the other hand, drug eluting self-expanding DES showed promise in avoiding the issue of malapposition in particular when there is a significant tapering of the distal left main [17] .
The bioresorbable scaffold (BRS) technology, in particular the absorb everolimus eluting scaffold, showed promising results when implanted in the LM [18] , however, the current unavailability of this device as well as the lack of data concerning other BRS make inappropriate any conclusion on this technology when applied to the LM.
| Assessment of left main stenosis severity
The left main segment is particularly prone to inter and intra observer variability, as well as to angiographic and catheter-related artifacts [19] .
As such, advanced imaging or physiologic lesion assessment is recommended in most cases. Intravascular ultrasound (IVUS) imaging is particularly useful to sort out left main stenosis severity: of note, the minimal lumen area (MLA) in the left main is not significantly different when assessed from pullback of the IVUS catheter from LAD or the left circumflex (LCX) [20] . North American populations [24] .
The FFR-determined left main MLA cutoff of 6 mm 2 has been prospectively validated in the LITRO trial [25] . In this study, the 179 patients with a left main MLA >6 mm 2 for whom left main revascularization was deferred had similar 2-year outcomes compared to those The use of FFR in moderate lesion without proof of ischemia has received Class I A indication in the U.S. guidelines [1, 2] and the capacity of FFR to reclassify patients with angiographic multivessel disease [31] is crucial to assess the true ischemic burden although, as previously mentioned, current European Guidelines still refers to the SYNTAX score, which is a purely anatomical score.
| Left main stenting
As compared to ostial and/or shaft PCI, distal left main intervention (which is typically at least a bifurcation) can be demanding (Figure 1 ).
The preferred stenting strategy is usually a planned single-stent "Provi- For all these techniques, the choice of the guiding catheter and intracoronary wires is clearly dependent on the operator's routine and discretion; however, for left main PCI a very supportive guiding catheter is usually unnecessary, as well as very stiff intracoronary wires with/ without high performance tips. Moreover, considering that hydrophilic wires have a higher capacity of dissecting and that the attention of the operator is basically focused on the proximal segments of the left coronary system, avoidance of hydrophilic wires seems reasonable, although, when crossing the stent struts they could be of help.
Evidence supporting which technique should be preferred for a specific anatomic conditions are scarce (see Figure 5 for a general technical guidance). In the DK Crush-III trial, 419 patients with UPLM disease were randomized to PCI with a culotte or double-kissing crush 
| Role of dual antiplatelet therapy
There is currently no specific indication within the guidelines as for the specific type and duration of the dual antiplatelet therapy after LM PCI [1, 2] , perhaps no study specifically addressed this issue. Thus, it is conceivable to keep the patient on DAPT for at least 12 months, or even more according to a thorough evaluation of the specific risk of ischemic and bleeding complications.
| CON CL U S I ON
The prognosis of patients with UPLM can be successfully improved with either PCI or CABG [37] ; however, all patients with complex CAD involving UPLM should be carefully evaluated by the Heart Team, which is the appropriate setting to discuss these challenging patients.
When the treatment of choice is percutaneous, the implementation of the most recent technologies and techniques is required in order to optimize the results. | 5
